drugset / Trial / NCT00137332

Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

NCT00137332 ↗

Phase 2 Terminated 90 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.

Timeline

Start
2005-11
Primary completion
—
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GAP-486 Unknown — —